326 related articles for article (PubMed ID: 29391754)
1. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates.
Gadiparthi C; Cholankeril G; Perumpail BJ; Yoo ER; Satapathy SK; Nair S; Ahmed A
World J Gastroenterol; 2018 Jan; 24(3):315-322. PubMed ID: 29391754
[TBL] [Abstract][Full Text] [Related]
2. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
Tapper EB; Afdhal NH; Curry MP
Transplantation; 2017 May; 101(5):933-937. PubMed ID: 28437385
[TBL] [Abstract][Full Text] [Related]
3. A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?
Barsa JE; Branch AD; Schiano TD
Clin Transplant; 2015 Oct; 29(10):859-65. PubMed ID: 26329668
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
5. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States.
Kwong A; Kim WR; Mannalithara A; Heo NY; Udompap P; Kim D
Liver Transpl; 2018 Jun; 24(6):735-743. PubMed ID: 29125676
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
7. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
9. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
13. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
[TBL] [Abstract][Full Text] [Related]
15. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
Gambato M; Lens S; Navasa M; Forns X
J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
[TBL] [Abstract][Full Text] [Related]
16. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
18. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
19. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
20. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]